药明康德旗下新药开发公司减资至约25.8亿，降幅约79%

Core Viewpoint - Recently, Shanghai WuXi AppTec New Drug Development Co., Ltd. has undergone a significant change in its registered capital, reducing from approximately 12.46 billion RMB to about 2.58 billion RMB, representing a decrease of approximately 79% [1][1]. Company Summary - The company was established in April 2002 and is wholly owned by WuXi AppTec (603259) [1]. - The legal representative of the company is Zhang Chaohui [1]. - The business scope includes health consulting, pharmaceutical consulting, and self-owned real estate development [1].